Paris bioabsorbable stent company appoints new CEO
Arterial Remodeling Technologies (ART) has appointed Machiel Van Der Leest as its CEO, effective immediately.
Van Der Leest has been ART’s chief operating officer since March. Previously, the Paris-based company said that he was director of research and development and regulatory affairs since May 2003 at Minvasys, a medical device maker focused on bifurcation device in Genevilliers, France.
“Because of ART’s approach of achieving temporary stenting of a traumatized angioplasty site, the company expects to benefit greatly from Machiel’s proven understanding of the development, regulatory, clinical, manufacturing and market dynamics of the bioresorbable stent sector,” said ART Director Thierry Chignon, MD, director of investments at Matignon Technologies.
Van Der Leest has been ART’s chief operating officer since March. Previously, the Paris-based company said that he was director of research and development and regulatory affairs since May 2003 at Minvasys, a medical device maker focused on bifurcation device in Genevilliers, France.
“Because of ART’s approach of achieving temporary stenting of a traumatized angioplasty site, the company expects to benefit greatly from Machiel’s proven understanding of the development, regulatory, clinical, manufacturing and market dynamics of the bioresorbable stent sector,” said ART Director Thierry Chignon, MD, director of investments at Matignon Technologies.